56421
document
Clinical efficacy of antazoline in rapid cardioversion of paroxysmal atrial fibrillation -- a protocol of a single center , randomized , double-blind , placebo-controlled study ( the AnPAF Study ) . BACKGROUND Rapid conversion of atrial fibrillation ( AF ) to sinus rhythm may be achieved by the administration of class IA , IC and III antiarrhythmic drugs or vernakalant hydrochloride . However , that treatment may be related to potential pro-arrhythmia , lack of efficacy or the exceptionally high cost of a compound used . Antazoline is a first generation antihistaminic agent with chinidin-like properties . When administered intravenously , antazoline exerts a strong antiarrhythmic effect on supraventricular arrhythmia , especially on AF , facilitating rapid conversion to sinus rhythm . Despite a relative lack of published data antazoline has been marketed in Poland and widely used in cardiology wards and emergency rooms for many years due to its efficacy , safety and rapid onset of action within minutes of administration . METHODS/DESIGN A randomized , double blind , placebo-controlled , superiority clinical trial was designed to assess clinical efficacy of antazoline in rapid conversion of AF to sinus rhythm . Eligible patients will present AF lasting less than 43 hours , will be in stable cardio-pulmonary condition and will have no prior history of advanced heart failure or significant valvular disease . Long-term antiarrhythmic therapy is not considered an exclusion criterion . Subjects who fulfill selection criteria will be randomly assigned to receive intravenously either antazoline or placebo in divided doses and observed for 1.5 hours after conversion to sinus rhythm or after the last i.v . bolus . Primary end point will be the conversion of AF to sinus rhythm confirmed in an electrocardiogram ( ECG ) during the observation period . Secondary end points will be comprised of time to conversion and return of AF during the observation period . Special consideration will be given to the observation of any adverse events . A sample size of 80 patients was calculated based on the following assumptions : two-tailed test , a type I error of 0.01 , a power of 90 % , efficacy of placebo 5 % , efficacy of antazoline 50 % and 20 % drop-out rate to fulfill the criteria of intention-to-treat analysis . Due to the presumed lack of statistical power , the secondary end points and safety endpoints will be considered exploratory . CLINICAL TRIALS REGISTRY ClinicalTrials.gov , NCT01527279 .
56422
Intervention_Pharmacological
antazoline
56423
Intervention_Pharmacological
class IA , IC and III antiarrhythmic drugs
56424
Intervention_Pharmacological
vernakalant hydrochloride
56425
Intervention_Pharmacological
Antazoline
56426
Intervention_Pharmacological
antazoline
56427
Intervention_Control
placebo-controlled
56428
Intervention_Pharmacological
antazoline
56429
Intervention_Pharmacological
antazoline
56430
Intervention_Control
placebo
56431
Intervention_Control
placebo
56432
Intervention_Pharmacological
antazoline
56433
Outcome_Physical
Rapid conversion of atrial fibrillation ( AF ) to sinus rhythm
56434
Outcome_Physical
strong antiarrhythmic effect
56435
Outcome_Physical
supraventricular arrhythmia
56436
Outcome_Physical
AF
56437
Outcome_Physical
rapid conversion to sinus rhythm
56438
Outcome_Other
clinical efficacy
56439
Outcome_Physical
conversion of AF to sinus rhythm confirmed in an electrocardiogram ( ECG )
56440
Outcome_Physical
comprised of time to conversion and return of AF
56441
Outcome_Adverse-effects
adverse events .
56442
Outcome_Other
efficacy
56443
Participant_Condition
paroxysmal atrial fibrillation -- a